Stay updated on Pembrolizumab in Untreated B-Cell NHL Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Untreated B-Cell NHL Clinical Trial page.

Latest updates to the Pembrolizumab in Untreated B-Cell NHL Clinical Trial page
- Check5 days agoChange DetectedThe page’s footer revision/version has been updated from v3.5.2 to v3.5.3 for the ClinicalTrials.gov site software.SummaryDifference0.1%

- Check12 days agoChange DetectedUpdated the site's release label from Revision: v3.5.0 to Revision: v3.5.2.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check41 days agoChange DetectedAdded: Revision v3.5.0; Removed: Revision v3.4.3.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page now displays Revision: v3.4.3, replacing the previous Revision: v3.4.2.SummaryDifference0.1%

- Check77 days agoChange DetectedRevision: v3.4.2 has been added. The government funding lapse notice and the older Revision: v3.4.1 entry were removed.SummaryDifference0.4%

- Check84 days agoChange DetectedA new site-wide notice about government funding status was added and the page revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab in Untreated B-Cell NHL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Untreated B-Cell NHL Clinical Trial page.